Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LMDX

LumiraDx (LMDX) Stock Price, News & Analysis

LumiraDx logo

About LumiraDx Stock (NASDAQ:LMDX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.0076
$0.0160
52-Week Range
N/A
Volume
132.24 million shs
Average Volume
56.75 million shs
Market Capitalization
$5.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Remove Ads
Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Stock News Headlines

LumiraDx Ltd LMDXF
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
LMDX.O
Why Is LumiraDx (LMDX) Stock Down 13% Today?
See More Headlines

LMDX Stock Analysis - Frequently Asked Questions

LumiraDx Limited (NASDAQ:LMDX) released its earnings results on Thursday, August, 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The business had revenue of $21 million for the quarter, compared to the consensus estimate of $21.07 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that LumiraDx investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), Abbott Laboratories (ABT), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Wayfair (W).

Company Calendar

Last Earnings
8/24/2023
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMDX
Fax
N/A
Employees
1,210
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-447,790,000.00
Net Margins
-268.45%
Pretax Margin
-264.58%

Debt

Sales & Book Value

Annual Sales
$126.52 million
Price / Cash Flow
N/A
Book Value
($0.33) per share
Price / Book
N/A

Miscellaneous

Free Float
205,749,000
Market Cap
$5.10 million
Optionable
Not Optionable
Beta
1.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:LMDX) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners